Analyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read...
IOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic...
